By Colin Kellaher Eli Lilly & Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive scientific opinion for the company's antibody-based Covid-19 drugs aimed at helping people at high risk of severe disease avoid hospitalization. The Indianapolis drugmaker said the opinion covers its monoclonal antibody bamlanivimab alone and in combination with one named etesevimab for the treatment of confirmed Covid-19 in patients ages 12 years and older who don't need supplemental oxygen and are at high risk of progressing to severe Covid-19. Monoclonal antibodies are engineered proteins that mimic the immune system's ability to fight off viruses.